About US
Contact us
-
Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall's lung medsAstraZeneca ($AZN) is staring down the barrel at rivals for its blockbuster respiratory drugSymbicort, branded and generic. CEO Pascal Soriot has respiratory drugs on his list of growth drivers. He's2014/7/31
-
Will he or won't he? Pfizer CEO scouts big deals, but 'silent' on AstraZeneca rebidNo news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEOIan Read's next buyout move was disappointed after Tuesday's second-quarter earnings2014/7/31
-
J&J, Pharmacyclics celebrate yet another nod for leukemia med ImbruvicaJohnson & Johnson's ($JNJ) new blood cancer drugImbruvica(ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic leukemia, adding to a series of regulato2014/7/30
-
China sets trial date for GSK-tied investigators, says it will be 'open'It's official: China has set the date for the trial of two private investigators tied to GlaxoSmithKline's operations there. The pair will head to court in just over a week on charges of illegally pur2014/7/30
-
Roche, Novartis protest moves in EU to pay for off-label AvastinLast week,Francemade its move to knock the Novartis eye drugLucentisout of drug coverage and move its cheaper cousinAvastininto its place. Now, Novartis and its Lucentis partner Roche are fighting bac2014/7/29
-
Merck whacks 600 sales reps as part of 8,500 bloodlettingMerck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with the new" philosophy. Now 600 sal2014/7/28
-
FDA approves Gilead Sciences’ Zydelig for three types of blood cancersGilead Sciences has obtained US Food and Drug Administration (FDA) approval for its Zydelig (idelalisib) 150mg tablets for treatment of three B-cell blood cancers. Zydelig is an oral inhibitor of pho2014/7/28
-
Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, KadcylaBlame a strong Swiss franc on any falling sales and profits Roche ($RHHBY) put up in the first half of 2014, the company said Thursday. The Swiss pharma's cancer drugs certainly didn't cause the decli2014/7/25
-
NICE recommends Sucampo’s Amitiza for chronic idiopathic constipation treatmentThe UK National Institute of Health and Care Excellence (NICE) has recommended Sucampo Pharmaceuticals' Amitiza (lubiprostone) as a treatment option for chronic idiopathic constipation (CIC) and assoc2014/7/25
-
Aduro’s pancreatic cancer immunotherapy gets FDA breakthrough therapy designationThe US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Aduro BioTech's pancreatic cancer combination treatment that consists of its CRS-207 and GVAX Pancreas immuno2014/7/24